Evidence map›Paper›PMID 32622469›Full record

ReviewThe American journal of the medical sciences2020

Is Inhaled Furosemide a Potential Therapeutic for COVID-19?

Anja Brennecke, Laura Villar, Zhiyu Wang, Lisa M Doyle, Autumn Meek, Mark Reed, Christopher Barden, Donald F Weaver

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The American journal of the medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04588792 (Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19 - A Phase 2/3 Study), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04588792 phase2 / phase3terminatednot on this mapstarted 2021, after this paper: background citation

Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19 - A Phase 2/3 Study

TypeinterventionalSponsorDr. John MuscedereRan2021 to 2023Enrolled40ConditionsCovid19, Respiratory FailureArmsNebulized Furosemide, Nebulized Saline
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anja BrenneckeKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Laura VillarKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Zhiyu WangKrembil Research Institute, University Health Network, Toronto, Ontario, Canada; Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Lisa M DoyleKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Autumn MeekKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Mark ReedKrembil Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Christopher BardenKrembil Research Institute, University Health Network, Toronto, Ontario, Canada.
Donald F WeaverKrembil Research Institute, University Health Network, Toronto, Ontario, Canada; Faculty of Medicine, University of Toronto, Medical Sciences Building, Toronto, Ontario, Canada. Electronic address: dweaver@uhnres.utoronto.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potentially lethal infection caused by the novel Severe Acute Respiratory Disease Coronavirus-2 (SARS-CoV-2) has evolved into a global crisis. Following the initial viral infection is the host inflammatory response that frequently results in excessive secretion of inflammatory cytokines (e.g., IL-6 and TNFα), developing into a self-targeting, toxic "cytokine storm" causing critical pulmonary tissue damage. The need for a therapeutic that is available immediately is growing daily but the de novo development of a vaccine may take years. Therefore, repurposing of approved drugs offers a promising approach to address this urgent need. Inhaled furosemide, a small molecule capable of inhibiting IL-6 and TNFα, may be an agent capable of treating the Coronavirus Disease 2019 cytokine storm in both resource-rich and developing countries. Furosemide is a "repurpose-able" small molecule therapeutics, that is safe, easily synthesized, handled, and stored, and is available in reasonable quantities worldwide.

Indexed as

Administration, InhalationAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19FurosemideHumansImmunity, InnateInflammation MediatorsPandemicsPneumonia, ViralSARS-CoV-2Sodium Potassium Chloride Symporter InhibitorsAntiviral AgentsFurosemideInflammation MediatorsSodium Potassium Chloride Symporter InhibitorsCOVID-19Cytokine stormFurosemideIL-6SARS-CoV-2

Identifiers

PMID32622469
PMCPMC7833957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.